Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit.
Lori J WirthCosimo DuranteDuncan J ToplissEric WinquistEyal RobenshtokHiroyuki IwasakiMarkus LusterRossella EliseiSophie LeboulleuxMakato TaharaPublished in: The oncologist (2022)
Current evidence indicates that patients benefit most from lenvatinib treatment that is initiated earlier in advanced disease when the disease burden is low. A starting dose of lenvatinib 24 mg/day, with dose modifications as required, yields better outcomes as compared to 18 mg/day. Appropriate supportive care, including timely identification of adverse events, is essential to manage toxicities associated with lenvatinib, avoid longer dose interruptions, and maximize efficacy.